Fig. 2.
Intranasal and intra-mPFC injections of RvE1 produce antidepressant-like actions via BDNF release in the mPFC in LPS-induced depression model mice. a Experimental timeline for LPS challenge (0.8 mg/kg, i.p.), intra-mPFC infusion of either control IgG (200 ng/side) or BDNF nAb (200 ng/side), i.n. administration of either vehicle (0.5% ethanol/PBS) or RvE1 (10 ng/mouse), and behavioral testing. b Effects of intra-mPFC infusion of BDNF nAb and i.n. administration of RvE1 on LMA in LPS-challenged mice (interaction, F1,19 = 0.00995, p = 0.922; BDNF nAb, F1,19 = 0.177, p = 0.679; RvE1, F1,19 = 0.642, p = 0.433). c, d Effects of intra-mPFC infusion of BDNF nAb on the antidepressant-like actions of i.n. administration of RvE1 in the TST (c, interaction, F1,19 = 13.9, p = 0.0014) and FST (d, interaction, F1,19 = 5.50, p = 0.0300) in LPS-challenged mice. e Schematic representation of the mPFC infusion sites. Plates are from ref. 36. f Experimental timeline for LPS challenge, intra-mPFC infusion of control IgG (200 ng/side), RvE1 (50 pg/side) + control IgG, BDNF nAb (200 ng/side) or RvE1 + BDNF nAb, and behavioral testing. g–i Effects of intra-mPFC infusion of RvE1 with or without BDNF nAb on LMA (g, interaction, F1,25 = 1.07, p = 0.311; BDNF nAb, F1,25 = 0.811, p = 0.376; RvE1, F1,25 = 0.821, p = 0.374) and immobility time in the TST (h, interaction, F1,25 = 7.57, p = 0.0109) and FST (i, interaction, F1,25 = 9.92, p = 0.0042) in LPS-challenged mice. j Schematic representation of the mPFC infusion sites. Plates are from ref. 36. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Holm-Sidak’s post hoc test)